These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2143320)

  • 1. Protein-calorie malnutrition inhibits antitumor response to interleukin-2 immunotherapy.
    Lieberman MD; Reynolds J; Goldfine J; Shou J; Daly JM
    Surgery; 1990 Aug; 108(2):452-8; discussion 458-9. PubMed ID: 2143320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of acute and chronic protein-energy malnutrition on host antitumor immune mechanisms.
    Lieberman MD; Reynolds J; Redmond HP; Leon P; Shou J; Daly JM
    JPEN J Parenter Enteral Nutr; 1991; 15(1):15-21. PubMed ID: 1901102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of hepatocellular function on NK and T cell tumoricidal activity.
    Roughneen PT; Kulkarni S; Kumar SC; Kulkarni AD; Fanslow W; Pellis NR; Rowlands BJ
    Surgery; 1988 Nov; 104(5):888-93. PubMed ID: 2973140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.
    Redlinger RE; Shimizu T; Remy T; Alber S; Watkins SC; Barksdale EM
    J Pediatr Surg; 2003 Feb; 38(2):199-204. PubMed ID: 12596103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of interleukin 3 but not interleukin 2 or interferon production in the syngeneic mixed lymphocyte reaction.
    Suzuki R; Suzuki S; Igarashi M; Kumagai K
    J Immunol; 1986 Sep; 137(5):1564-72. PubMed ID: 2427574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
    Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of protein calorie malnutrition on the levels of natural and inducible cytotoxic activities in mouse spleen cells.
    Saxena QB; Saxena RK; Adler WH
    Immunology; 1984 Apr; 51(4):727-33. PubMed ID: 6423525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malnutrition-induced macrophage apoptosis.
    Rivadeneira DE; Grobmyer SR; Naama HA; Mackrell PJ; Mestre JR; Stapleton PP; Daly JM
    Surgery; 2001 May; 129(5):617-25. PubMed ID: 11331454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
    Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells.
    Sugarbaker PH; Matthews W; Steller EP; Eggermont AM
    J Biol Response Mod; 1987 Aug; 6(4):430-45. PubMed ID: 3498012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
    Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
    Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of tumor-derived heat shock protein 70 immunotherapy combining interleukin-2 on tumor-bearing mice.
    Fu Q; Meng F; Shen X; Guo R
    Chin Med J (Engl); 2003 Feb; 116(2):288-91. PubMed ID: 12775249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active suppression of host-vs-graft reaction in pregnant mice. VI. Soluble suppressor activity obtained from decidua of allopregnant mice blocks the response to IL 2.
    Clark DA; Chaput A; Walker C; Rosenthal KL
    J Immunol; 1985 Mar; 134(3):1659-64. PubMed ID: 3871455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.